Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received marketing approval in China for its core product, sacituzumab tirumotecan (sac-TMT), targeting advanced triple negative breast cancer. This approval follows promising results from a phase 3 study, showcasing significant improvements in patient survival rates compared to standard chemotherapy. The development marks a notable milestone for the company as it expands its footprint in the biopharmaceutical market.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.